Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

ABSTRACT Erythema multiforme (EM), an immune-mediated skin condition, can occur after infection or following the use of medications. In this study, we describe a patient who developed EM after nirmatrelvir/ritonavir administration. An 81-year-old woman presented with fever and dyspnea. Laboratory investigations showed positive coronavirus disease (COVID-19) based on polymerase chain reaction assay, and she received a 5-day regimen of nirmatrelvir/ritonavir. We observed development of EM after this treatment and initiated prednisone (1 mg/kg) therapy, which led to rapid improvement. Our study is the first to report EM in a patient with COVID-19, who received nirmatrelvir/ritonavir and showed a favorable response.摘要 多形红斑（Erythema multiforme，EM）是一种免疫介导性皮肤病，可在感染后或使用药物后诱发。本研究报告1例在服用奈玛特韦/利托那韦后出现多形红斑的患者：该患者为81岁女性，因发热、呼吸困难就诊。实验室检查通过聚合酶链反应检测证实其感染新型冠状病毒肺炎（COVID-19），随后接受了为期5天的奈玛特韦/利托那韦治疗方案。治疗后我们观察到患者出现多形红斑，遂给予泼尼松（prednisone）1 mg/kg治疗，患者症状迅速好转。本研究为首例报告新型冠状病毒肺炎患者服用奈玛特韦/利托那韦后出现多形红斑且治疗应答良好的病例。